Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety
Saved in:
Main Author: | Michael P. Isles (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Orphan drugs assessment in the centralised procedure
by: Giuseppe Nisticò
Published: (2011) -
Governing Finance in Europe: A Centralisation of Rulemaking?
by: Magnus G. Schoeller
Published: (2020) -
The decentralisation-centralisation dilemma: recruitment and distribution of health workers in remote districts of Tanzania
by: Songstad Nils, et al.
Published: (2009) -
Consequences of centralised blood bank policies in sub-Saharan Africa
by: Jared R Gallaher, et al.
Published: (2017) -
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions
by: Tanguturi Yella Sree Sudha, et al.
Published: (2024)